| Yttrium-90 Selective Internal Radiotherapy (SIRT–Y90) brings hope to liver cancer patients
According to the 2020 statistics from the Hong Kong Cancer Registry, liver cancer is the third leading cause of cancer death in Hong Kong. Fortunately, with recent advances, different treatment options are now available to bring new hope to patients. Yttrium-90 (abbreviated as Y90) selective internal radiotherapy (SIRT, also known as radioembolisation) is one of the recent treatment options suitable for patients who are suffering from primary liver cancer and metastatic liver cancer. Studies have shown a high objective response rate of 88% for primary tumours and also favourable result on metastatic tumours. In most cases, single treatment session is adequate to improve the patient's condition, said Dr Lau Wing-hang Vince, Gleneagles' Consultant in Radiology.
The Y90 procedure involves injecting microspheres into the blood vessels which supply the tumour. The microspheres then release radiation to control the tumour. Since Y90 is an internal radiotherapy, it has lower side effects and avoids the discomfort commonly associated with conventional trans-arterial chemoembolisation procedures. Also, when compared to traditional external radiotherapy, it is less prone to side effects such as redness, dryness, itchy skin and blister. 🔎Click here to view the article (*in Chinese only) in which Dr Lau Wing-hang Vince shares the principle and procedure of Y90 selective internal radiotherapy for liver cancer.
Y90體內放射治療 為肝癌患者帶來希望
香港癌症資料統計中心2020年的數據指出，肝癌位列本港致命癌症第三位。幸好，隨著醫學進步，現今亦提供不同的治療方案為肝癌患者帶來希望。
釔-90（簡稱Y90）微粒選擇性體內放射治療（或稱放射栓塞術），是近年治療肝癌方案之一，適用於患上原發性肝癌或因其他癌症轉移至肝臟的病人。港怡醫院放射科顧問醫生劉泳恆醫生指出，Y90療程對原發性的腫瘤客觀反應率高達88%，而對擴散性的腫瘤亦能達到理想效果。在大多數情況下，病人只需進行一次療程便能夠提升生活質素。
Y90手術透過注射微球體至腫瘤的供應血管，再釋放出輻射殺死腫瘤細胞。由於Y90屬於體內放射治療，副作用相對較低，不會出現一般肝動脈血管栓塞療程所帶來的痛楚，亦不會像接受傳統體外放射治療（俗稱電療）後容易出現皮膚發紅、乾燥、痕癢、起水泡等副作用。 🔎請按此閱讀文章，由劉泳恆醫生解說更多有關Y90放射治療肝癌的原理及治療過程。 | 
No comments:
Post a Comment